Nagel J, Namasivayam V, Weinhausen S, Sierra-Marquez J, Baqi Y, Al Musawi HAM, Abdelrahman A, Vaaßen VJ, Schlegel JG, Taplick L, Torp J, Kubick J, Maertens B, Geyer M, Claff T, Nicke A, Hagelueken G, Müller CE. Discovery of an allosteric binding site for anthraquinones at the human P2X4 receptor; Nature Communications; 16, Article number: 10367

Westermann FG, Okenc AC, Granithd PKE, Marimuthud P, Müller CE, Mansoor SE. Subtype- specific structural features of the hearing loss–rassociated human P2X2 receptor. PNAS. https://doi.org/10.1073/pnas.2417753122

Sun T, Zhai S, König B, Honin I, Kponomaizoun CE, Hansen FK. Targeted Degradation of Histone Deacetylases via Bypassing E3 Ligase Targeting Chimeras (BYETACs). ACS Med. Chem. Lett. 2025. doi: 10.1021/acsmedchemlett.5c00193.

Sun T, Zhai S, Lepper S, König B, Malenica M, Honin I, Hansen FK. DCAF16-Based Covalent Molecular Glues for Targeted Protein Degradation of Histone Deacetylases. Archiv der Pharmazie 2025; 358(7):e70045. doi: 10.1002/ardp.70045

Sugrue I, Ade C, O'Connor PM, Daniel JM, Innocenti P, Kirsch N, Martin NI, Weindl G, Hill C, Schneider T, Ross RP. Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins. NPJ Antimicrob. Resist. 2025 Jul 22;3(1):66. doi: 10.1038/s44259-025-00135-x. PMID: 40695989.

Nekipelov K, Nahain AA, Otto S, Xu Y, Li JP, Letunica N, Collett S, Attard C, Monagle P, Vamvounis G, Tsanaktsidis J, Ferro V, Bendas G. A Novel Series of Synthetic Heparin-Mimetics-Itaconic Acid-Containing Copolymers for Targeting Tumor Cell Coagulability and Metastasis. Macromol. Biosci. 2025; 25(7):e2400633. doi: 10.1002/mabi.202400633.

Mühle J, Alenfelder J, Rodrigues MJ, Jürgenliemke L, Guixà-González R, Grätz L, Andres F, Bacchin A, Hennig M, Schihada H, Crüsemann M, König GM, Schertler G, Kostenis E, Deupi X.. Cyclic peptide inhibitors function as molecular glues to stabilize Gq/11 heterotrimers. Proc. Natl. Acad. Sci. U S A 2025 May 13;122(19):e2418398122. doi: 10.1073/pnas.2418398122. Epub 2025 May 7.

Engelhardt J, Klawonn A, Dobbelstein AK, Abdelrahman A, Oldenburg J, Brandenburg K, Müller CE, Weindl G; Lipopolysaccharide-Neutralizing Peptide Modulates P2X7 Receptor-Mediated Interleukin-1β Release. ACS Pharmacol Transl Sci 8:136-145

Matziol T, Talagayev V, Slokan T, Strašek Benedik N, Holze J, Sova M, Wolber G, Weindl G; Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists. J Med Chem 68:4888-4907.

Bockstiegel J, Engelhardt J, Schuchardt M, Tölle M, Weindl G; The vasoconstrictor adenosine 5′-tetraphosphate is a danger signal that induces IL-1β. Mol Med 31:72.

Breuer C,  Küppers J, Schulz-Fincke AC, Heilos A, Lemke C, Spiwokowá P,  Schmitz J, Cremer L, Frigolé-Vivas M, Lülsdorff M, Mertens MD, Wichterle F, Apeltauer M, Horn M, Gilberg E, Furtmann N, Bajorath J, Bartz U, Engels B, Mareš M, Gütschow M; Redirecting the Peptide Cleavage Causes Protease Inactivation;Angew. Chem. Int. Ed. 2025, 

Zhai S, Kemkes M, Kponomaizoun CE, Feller F, Tu J-W, Pieńkowska DE, Gerhartz J, Schliehe-Diecks J, Gütschow M, Nowak RP, Steinebach C, Bhatia S, Hansen FK. Discovery of histone deacetylase 8 (HDAC8)-specific proteolysis-targeting chimeras with anti-cancer activity against hematological malignancies. ChemRxiv 2025. doi: 10.26434/chemrxiv-2025-fmh6q.

Zhai S, Honin I, Schäker-Hübner L, Hanl M, Jacobi L, Dressler F, Pieńkowska DE, König P, Gerhartz J, Voget R, Bendas G, Gütschow M, Meissner F, Burckhardt B, Nowak RP, Steinebach C, Hansen FK. Development and characterization of the first selective class IIb histone deacetylase degraders. ChemRxiv 2025. doi: 10.26434/chemrxiv-2024-ngppg-v3.

Wurnig SL, Huber ME, Weiler C, Baltrukevich H, Merten N, Stötzel I, Steffen T, Chang Y, Klammer RHL, Baumjohann D, Kiermaier E, Kolb P, Kostenis E, Schiedel M, Hansen FK.
A Fluorescent Probe Enables the Discovery of Improved Antagonists Targeting the Intracellular Allosteric Site of the Chemokine Receptor CCR7. J. Med. Chem. 2025; 68(4):4308–33. doi: 10.1021/acs.jmedchem.4c02102

Wurnig SL, Hanl M, Geiger TM, Zhai S, Dressel I, Pieńkowska DE, Nowak RP, Hansen FK.  Light-activatable photochemically targeting chimeras (PHOTACs) enable the optical control of targeted protein degradation of HDAC6. RSC Med. Chem. 2025. doi: 10.1039/D4MD00972J.

Stopper D, Honin I, Feller F, Hansen FK. Development of Ethyl-Hydrazide-Based Selective Histone Deacetylase 6 (HDAC6) PROTACs.
ACS Med. Chem. Lett. 2025; 16(3):487–95. doi: 10.1021/acsmedchemlett.5c00033.

Stopper D, Biermann L, Watson PR, Li j, König B, Gaynes MN, Pessanha de Carvalho L, Klose J, Hanl M, Hamacher A, Schäker-Hübner L, Ramsbeck D, Held J, Christianson DW, Kassack MU, Hansen FK. Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties. J. Med. Chem. 2025; 68(4):4426–52. doi: 10.1021/acs.jmedchem.4c02373.

Hanl M, Feller F, Honin I, Tan K, Schaeker-Huebner L, Bueckreiss N, Schiedel M, Guetschow M, Bendas G, Hansen FK. Target engagement studies and kinetic live-cell degradation assays enable the systematic characterization of HDAC6 PROTACs at endogenous protein expression levels. bioRxiv 2025. doi: 10.1101/2025.03.31.646177.

Feller F, Weber H, Miranda M, Honin I, Hanl M, Hansen FK. Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts Selective Histone Deacetylase 6 PROTAC into a Pan-Degrader. ChemMedChem 2025:e202500035. doi: 10.1002/cmdc.202500035.

Al Hamwi G, Alnouri MW, Verdonck S, Leonczak P, Chaki S, Frischbutter S, Kolkhir P, Michaela Matthey M, Kopp C, Bednarski M, Riedel YK, Marx D, Clemens S, Namasivayam V, Gattner S, Thimm D, Sylvester K, Wolf K. Kremer AE, De Jonghe S, Wenzel D, Kotańska M, Ali H, Herdewijn P, Müller CE. Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models; Signal Transduction and Targeted Therapy. DOI: 10.1038/s41392-025-02209-8

Bhattarai K, Majer T, Haussmann M, Schollmeyer D, Oni FE, Höfte M, Voget R, Gütschow M, Ruetalo N, Schindler M, Straetener J, Wannenwetsch T, Brötz-Oesterhelt H, Karongo R, Lämmerhofer M, Hennessy RC, Muletz-Wolz CR, Gross H; Salamandamide Lipodipeptides are Biosynthetic Intermediate Shunt Products of the Nonamodular Nonribosomal Peptide Assembly Lines of the Viscosin Family; J. Nat. Prod. 2025, 88, 1012-1022. 

Keuler T, Ferber D, Engelhardt J, Steinebach C, Kirsch N, Marleaux M, Weindl G , Geyer M, Gütschow M; Degrading the Key Component of the Inflammasome: Development of an NLRP3 PROTAC; Chem. Commun. 2025, 61, 3001-3004.

Perzolli A, Steinebach C, Krönke J, Gütschow M, Zwaan CM, Barneh F, Heidenreich O.; PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia; Cancers, 2025, 17, 211.

Flury P, Krüger N, Sylvester K, Breidenbach J, Al Hamwi G, Qiao J, Chen Y, Rocha C, Serafim MSM, Barbosa da Silva E, Pöhlmann S, Poso A, Kronenberger T, Rox K, O'Donoghue AJ, Yang S, Sträter N, Gütschow M, Laufer SA, Müller CE, Pillaiyar T; Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and Its Variants Displaying Potent Antiviral Activity; J. Med. Chem. 2025, 68, 3626-3652.

Feller F, Honin I, Miranda M, Weber H, Henze S, Hanl M, Hansen FK. Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders. J Med Chem 2025. doi: 10.1021/acs.jmedchem.4c02569.

Stopper D, Buntrock S, Tan K, Carvalho LP de, Schäker-Hübner L, Held J, Kassack MU, Hansen FK. Multicomponent syntheses enable the discovery of novel quisinostat-derived chemotypes as histone deacetylase inhibitors. Eur J Med Chem 2025; 281:117045. doi: 10.1016/j.ejmech.2024.117045.